Dr. E. Vance
Editorial Director, PeptiDex
Dr. E. Vance is the Editorial Director at PeptiDex and leads the platform's editorial division, ensuring that every published research summary meets rigorous preclinical citation standards. With a Ph.D. in Molecular Pharmacology from Columbia University and over 12 years of experience in peptide research, Dr. Vance has authored and reviewed over 200 published analyses covering growth hormone secretagogues, healing peptides, and regulatory pharmacology. Before founding PeptiDex's editorial program, Dr. Vance served as a Senior Research Fellow at the Scripps Research Institute, where his work focused on peptide receptor binding kinetics and structure-activity relationships. He is a member of the American Chemical Society and the American Society for Pharmacology and Experimental Therapeutics (ASPET).
Areas of Expertise
Published Articles (4)
Are Peptides Safe? What the Research Says in 2026
A research-backed safety analysis of popular peptides including BPC-157, semaglutide, and GHK-Cu — covering clinical safety data, purity risks, and side effect profiles.
BPC-157 vs TB-500: What the Research Actually Shows
An in-depth analysis of the synergistic mechanisms between BPC-157 and TB-500 for musculoskeletal tissue repair and inflammation reduction.
How to Read a Peptide COA (And Why It Matters)
Avoid dangerous synthesis byproducts by learning how to properly analyze independent HPLC and mass spectrometry reports before sourcing.
Best Peptide Vendors 2026: Independently Reviewed & COA Verified
We independently evaluate peptide vendors based on third-party COA testing, purity verification, shipping speed, and pricing. Updated monthly for April 2026.
Learn more about our editorial standards and the full PeptiDex team.
Meet the Full TeamPeptiDex is an independent educational platform. Author credentials are self-reported and verified internally. Nothing on this page constitutes medical advice. All content is for research and educational purposes only.